ViroGates Q1-Q3 2026 net loss narrows 29% to DKK 5.68 million
ViroGates Q1-Q3 2026 net loss narrows 29% to DKK 5.68 million ViroGates’ Q1-Q3 2026 net loss nar
Related stories
Enovis Climbs on Swing to 3Q Profit, Higher Sales
By Connor HartShares of Enovis gained after the medical-technology company swung to a profit and logged higher sales in the recent quarter, prompting it to raise its full-year outl
L impact | EARNINGS | Nov 05, 2026, 05:05 PM UTC
Warby Parker Shares Up on Higher Rev Guidance Mid-Point, Higher 3Q Rev
By Natalie WegerShares of Warby Parker climbed after the company raised the bottom of its full-year sales guidance and said it's on track to launch its intelligent eyewear.Shares c
L impact | EARNINGS | Nov 05, 2026, 05:05 PM UTC
Azimut Reports 9M 2026 Results, Reaffirms Full-Year Guidance
Recurring net profit rose 4% to €382 million and recurring EBIT increased 10% to €485 million. Recurring revenue grew 15%, while total assets reached €159 billion. The company reaf
M impact | EARNINGS | Nov 05, 2026, 05:03 PM UTC
Pirelli Sees 2026 Revenue at EUR6.85B-EUR6.95B
M impact | EARNINGS | Nov 05, 2026, 05:03 PM UTC
Vicat Raises 2026 Organic Revenue Growth Outlook to 8%-10%
M impact | EARNINGS | Nov 05, 2026, 05:02 PM UTC
Genmab Reports Nine-Month Revenue of $3.24 Billion, Maintains 2026 Guidance
Revenue rose 22% year over year to $3.24 billion for the nine months ended September 30, 2026. Genmab reported operating profit of $986 million and net profit of $698 million.
M impact | EARNINGS | Nov 05, 2026, 05:02 PM UTC